Eagle Pharmaceuticals Inc (EGRX) Releases Earnings Results, Beats Expectations By $0.24 EPS

Eagle Pharmaceuticals Inc (EGRX) reported quarterly earnings results on Monday, May-9-2016. The company said it had a profit of $-0.06 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.24. Analysts had a consensus of $-0.30. The company posted revenue of $29.60 million in the period, compared to analysts expectations of $14.26 million. The company’s revenue was down -18.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.31 EPS.

Many Wall Street Analysts have commented on Eagle Pharmaceuticals Inc. Shares were Reiterated by Mizuho on Mar 18, 2016 to “Buy” and Lowered the Price Target to $ 71 from a previous price target of $81 .Shares were Reiterated by Mizuho on Feb 26, 2016 to “Buy” and Lowered the Price Target to $ 81 from a previous price target of $112 .

Eagle Pharmaceuticals Inc closed down -0.51 points or -1.41% at $35.75 with 3,71,004 shares getting traded on Friday. Post opening the session at $36.04, the shares hit an intraday low of $34.698 and an intraday high of $36.95 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Apr 5, 2016, Scott Tarriff (President and CEO) sold 30,765 shares at $40.63 per share price. According to the SEC, on Mar 16, 2016, Michael Graves (director) purchased 1,000 shares at $56.73 per share price. On Dec 23, 2015, Sander A Flaum (director) sold 13,025 shares at $67.88 per share price, according to the Form-4 filing with the securities and exchange commission.

Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.

Eagle Pharmaceuticals Inc

Leave a Reply

Eagle Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eagle Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.